内分泌科

订阅

MedSci主页 / 所有栏目 / 内分泌科

Lancet：2型糖尿病治疗，礼来tirzepatide临床击败“网红降糖药”索马鲁肽！

2021-08-14 MedSci原创 MedSci原创

达格列净索马鲁特
关注

在2型糖尿病患者中，tirzepatide优于胰岛素，在第52周时HbA1c和体重的降低幅度更大，低血糖风险更低。

2型糖尿病（T2DM）是一种代谢紊乱，机体对胰岛素不敏感，出现高血糖症状。Tirzepatide是最近最受瞩目的新型降糖药之一，它是一种每周注射一次的GIP和GLP-1受体双重激动剂，可将两种肠促胰岛素的作用整合到一个分子中，代表治疗2型糖尿病的一类新手段。 GIP是一种激素，可能补充GLP-1受体激动剂的作用。在临床前模型中，已证明GIP可减少摄食量并增加能量消耗，因此导致体重减轻，当与GLP-1受体激动剂联合使用时，可能对葡萄糖水平和体重产生更大影响。 2021年3月4日，礼来公布了进行40周的3期临床试验SURPASS-2结果，数据显示，与诺和诺德1毫克注射用semaglutide（索马鲁肽）相比，三种剂量的tirzepatide均能使成人II型糖尿病患者的糖化血红蛋白和体重从基线水平显著降低。 近期，为了评估tirzepatide与滴定胰岛素相比，适用于使用或不使用SGLT2抑制剂的二甲双胍控制不佳的2型糖尿病患者的疗效和安全性，来自奥地利第一医学部和卡尔-兰德斯坦纳肥胖症和代谢紊乱研究所开展了相关研究，结果发表在Lancet杂志上。 在这项开放标签、平行分组、多中心（122个

评论区 (10)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1214247, encodeId=91fa121424e06, content=<a href='/topic/show?id=16b6104504ef' target=_blank style='color:#2F92EE;'>#泰瑞帕肽#</a>大于<a href='/topic/show?id=1090e69928f' target=_blank style='color:#2F92EE;'>#索马鲁肽#</a>，更大于<a href='/topic/show?id=401e3230391' target=_blank style='color:#2F92EE;'>#利拉鲁肽#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=150, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=104504, encryptionId=16b6104504ef, topicName=泰瑞帕肽), TopicDto(id=76992, encryptionId=1090e69928f, topicName=索马鲁肽), TopicDto(id=32303, encryptionId=401e3230391, topicName=利拉鲁肽)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211210/ede9c51184aa4f54ae6c1164cfb8eeac/967dbf3eff2943c7bf3ccfec3a776ab0.JPG, createdBy=a33789389, createdName=病毒猎手, createdTime=Mon Apr 25 22:19:18 CST 2022, time=2022-04-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1062655, encodeId=1e9c1062655ef, content=新的方法，新的起点, beContent=null, objectType=article, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210826/7a6cce5e03844bcf8a6ee8a36dba8188/b15bf50504094d3aa56a8f1a32d3304c.jpg, createdBy=1d8c1533153, createdName=未来将来, createdTime=Thu Oct 21 17:31:07 CST 2021, time=2021-10-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1831273, encodeId=8b7518312e3c5, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Fri May 13 22:38:42 CST 2022, time=2022-05-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1990000, encodeId=b15f19900006b, content=<a href='/topic/show?id=3207e6735ae' target=_blank style='color:#2F92EE;'>#糖尿病治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=118, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76735, encryptionId=3207e6735ae, topicName=糖尿病治疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e6a1280, createdName=zhanglin3079, createdTime=Mon Jan 17 02:38:42 CST 2022, time=2022-01-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1270929, encodeId=ec5412e0929c6, content=<a href='/topic/show?id=4066981e99e' target=_blank style='color:#2F92EE;'>#降糖药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98179, encryptionId=4066981e99e, topicName=降糖药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Mon Aug 16 09:38:42 CST 2021, time=2021-08-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1404244, encodeId=feb0140424436, content=<a href='/topic/show?id=ff77e94785a' target=_blank style='color:#2F92EE;'>#网红#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79478, encryptionId=ff77e94785a, topicName=网红)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=981e2448917, createdName=caoliehu, createdTime=Mon Aug 16 09:38:42 CST 2021, time=2021-08-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1427544, encodeId=99fb142e544cb, content=<a href='/topic/show?id=221d685172' target=_blank style='color:#2F92EE;'>#EPA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6851, encryptionId=221d685172, topicName=EPA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4a9b4077760, createdName=gwc384, createdTime=Mon Aug 16 09:38:42 CST 2021, time=2021-08-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1034423, encodeId=b606103442359, content=顶刊就是不一样，质量很高，内容精彩！学到很多, beContent=null, objectType=article, channel=null, level=null, likeNumber=105, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=goodbing, createdTime=Sat Aug 14 21:38:42 CST 2021, time=2021-08-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1043734, encodeId=f3221043e3420, content=谢谢MedSci提供最新的资讯, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Sat Aug 14 21:38:42 CST 2021, time=2021-08-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1007906, encodeId=fad9100e906ab, content=学习学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=107, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=b3545492917, createdName=smart Ren, createdTime=Sat Aug 14 20:13:10 CST 2021, time=2021-08-14, status=1, ipAttribution=)]
    2022-04-25 病毒猎手

    #泰瑞帕肽#大于#索马鲁肽#，更大于#利拉鲁肽#

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1214247, encodeId=91fa121424e06, content=<a href='/topic/show?id=16b6104504ef' target=_blank style='color:#2F92EE;'>#泰瑞帕肽#</a>大于<a href='/topic/show?id=1090e69928f' target=_blank style='color:#2F92EE;'>#索马鲁肽#</a>，更大于<a href='/topic/show?id=401e3230391' target=_blank style='color:#2F92EE;'>#利拉鲁肽#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=150, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=104504, encryptionId=16b6104504ef, topicName=泰瑞帕肽), TopicDto(id=76992, encryptionId=1090e69928f, topicName=索马鲁肽), TopicDto(id=32303, encryptionId=401e3230391, topicName=利拉鲁肽)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211210/ede9c51184aa4f54ae6c1164cfb8eeac/967dbf3eff2943c7bf3ccfec3a776ab0.JPG, createdBy=a33789389, createdName=病毒猎手, createdTime=Mon Apr 25 22:19:18 CST 2022, time=2022-04-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1062655, encodeId=1e9c1062655ef, content=新的方法，新的起点, beContent=null, objectType=article, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210826/7a6cce5e03844bcf8a6ee8a36dba8188/b15bf50504094d3aa56a8f1a32d3304c.jpg, createdBy=1d8c1533153, createdName=未来将来, createdTime=Thu Oct 21 17:31:07 CST 2021, time=2021-10-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1831273, encodeId=8b7518312e3c5, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Fri May 13 22:38:42 CST 2022, time=2022-05-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1990000, encodeId=b15f19900006b, content=<a href='/topic/show?id=3207e6735ae' target=_blank style='color:#2F92EE;'>#糖尿病治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=118, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76735, encryptionId=3207e6735ae, topicName=糖尿病治疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e6a1280, createdName=zhanglin3079, createdTime=Mon Jan 17 02:38:42 CST 2022, time=2022-01-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1270929, encodeId=ec5412e0929c6, content=<a href='/topic/show?id=4066981e99e' target=_blank style='color:#2F92EE;'>#降糖药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98179, encryptionId=4066981e99e, topicName=降糖药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Mon Aug 16 09:38:42 CST 2021, time=2021-08-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1404244, encodeId=feb0140424436, content=<a href='/topic/show?id=ff77e94785a' target=_blank style='color:#2F92EE;'>#网红#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79478, encryptionId=ff77e94785a, topicName=网红)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=981e2448917, createdName=caoliehu, createdTime=Mon Aug 16 09:38:42 CST 2021, time=2021-08-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1427544, encodeId=99fb142e544cb, content=<a href='/topic/show?id=221d685172' target=_blank style='color:#2F92EE;'>#EPA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6851, encryptionId=221d685172, topicName=EPA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4a9b4077760, createdName=gwc384, createdTime=Mon Aug 16 09:38:42 CST 2021, time=2021-08-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1034423, encodeId=b606103442359, content=顶刊就是不一样，质量很高，内容精彩！学到很多, beContent=null, objectType=article, channel=null, level=null, likeNumber=105, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=goodbing, createdTime=Sat Aug 14 21:38:42 CST 2021, time=2021-08-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1043734, encodeId=f3221043e3420, content=谢谢MedSci提供最新的资讯, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Sat Aug 14 21:38:42 CST 2021, time=2021-08-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1007906, encodeId=fad9100e906ab, content=学习学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=107, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=b3545492917, createdName=smart Ren, createdTime=Sat Aug 14 20:13:10 CST 2021, time=2021-08-14, status=1, ipAttribution=)]
    2021-10-21 未来将来

    新的方法，新的起点

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1214247, encodeId=91fa121424e06, content=<a href='/topic/show?id=16b6104504ef' target=_blank style='color:#2F92EE;'>#泰瑞帕肽#</a>大于<a href='/topic/show?id=1090e69928f' target=_blank style='color:#2F92EE;'>#索马鲁肽#</a>，更大于<a href='/topic/show?id=401e3230391' target=_blank style='color:#2F92EE;'>#利拉鲁肽#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=150, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=104504, encryptionId=16b6104504ef, topicName=泰瑞帕肽), TopicDto(id=76992, encryptionId=1090e69928f, topicName=索马鲁肽), TopicDto(id=32303, encryptionId=401e3230391, topicName=利拉鲁肽)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211210/ede9c51184aa4f54ae6c1164cfb8eeac/967dbf3eff2943c7bf3ccfec3a776ab0.JPG, createdBy=a33789389, createdName=病毒猎手, createdTime=Mon Apr 25 22:19:18 CST 2022, time=2022-04-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1062655, encodeId=1e9c1062655ef, content=新的方法，新的起点, beContent=null, objectType=article, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210826/7a6cce5e03844bcf8a6ee8a36dba8188/b15bf50504094d3aa56a8f1a32d3304c.jpg, createdBy=1d8c1533153, createdName=未来将来, createdTime=Thu Oct 21 17:31:07 CST 2021, time=2021-10-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1831273, encodeId=8b7518312e3c5, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Fri May 13 22:38:42 CST 2022, time=2022-05-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1990000, encodeId=b15f19900006b, content=<a href='/topic/show?id=3207e6735ae' target=_blank style='color:#2F92EE;'>#糖尿病治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=118, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76735, encryptionId=3207e6735ae, topicName=糖尿病治疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e6a1280, createdName=zhanglin3079, createdTime=Mon Jan 17 02:38:42 CST 2022, time=2022-01-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1270929, encodeId=ec5412e0929c6, content=<a href='/topic/show?id=4066981e99e' target=_blank style='color:#2F92EE;'>#降糖药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98179, encryptionId=4066981e99e, topicName=降糖药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Mon Aug 16 09:38:42 CST 2021, time=2021-08-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1404244, encodeId=feb0140424436, content=<a href='/topic/show?id=ff77e94785a' target=_blank style='color:#2F92EE;'>#网红#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79478, encryptionId=ff77e94785a, topicName=网红)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=981e2448917, createdName=caoliehu, createdTime=Mon Aug 16 09:38:42 CST 2021, time=2021-08-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1427544, encodeId=99fb142e544cb, content=<a href='/topic/show?id=221d685172' target=_blank style='color:#2F92EE;'>#EPA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6851, encryptionId=221d685172, topicName=EPA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4a9b4077760, createdName=gwc384, createdTime=Mon Aug 16 09:38:42 CST 2021, time=2021-08-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1034423, encodeId=b606103442359, content=顶刊就是不一样，质量很高，内容精彩！学到很多, beContent=null, objectType=article, channel=null, level=null, likeNumber=105, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=goodbing, createdTime=Sat Aug 14 21:38:42 CST 2021, time=2021-08-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1043734, encodeId=f3221043e3420, content=谢谢MedSci提供最新的资讯, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Sat Aug 14 21:38:42 CST 2021, time=2021-08-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1007906, encodeId=fad9100e906ab, content=学习学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=107, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=b3545492917, createdName=smart Ren, createdTime=Sat Aug 14 20:13:10 CST 2021, time=2021-08-14, status=1, ipAttribution=)]
    2022-05-13 howi

    #Lancet#

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1214247, encodeId=91fa121424e06, content=<a href='/topic/show?id=16b6104504ef' target=_blank style='color:#2F92EE;'>#泰瑞帕肽#</a>大于<a href='/topic/show?id=1090e69928f' target=_blank style='color:#2F92EE;'>#索马鲁肽#</a>，更大于<a href='/topic/show?id=401e3230391' target=_blank style='color:#2F92EE;'>#利拉鲁肽#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=150, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=104504, encryptionId=16b6104504ef, topicName=泰瑞帕肽), TopicDto(id=76992, encryptionId=1090e69928f, topicName=索马鲁肽), TopicDto(id=32303, encryptionId=401e3230391, topicName=利拉鲁肽)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211210/ede9c51184aa4f54ae6c1164cfb8eeac/967dbf3eff2943c7bf3ccfec3a776ab0.JPG, createdBy=a33789389, createdName=病毒猎手, createdTime=Mon Apr 25 22:19:18 CST 2022, time=2022-04-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1062655, encodeId=1e9c1062655ef, content=新的方法，新的起点, beContent=null, objectType=article, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210826/7a6cce5e03844bcf8a6ee8a36dba8188/b15bf50504094d3aa56a8f1a32d3304c.jpg, createdBy=1d8c1533153, createdName=未来将来, createdTime=Thu Oct 21 17:31:07 CST 2021, time=2021-10-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1831273, encodeId=8b7518312e3c5, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Fri May 13 22:38:42 CST 2022, time=2022-05-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1990000, encodeId=b15f19900006b, content=<a href='/topic/show?id=3207e6735ae' target=_blank style='color:#2F92EE;'>#糖尿病治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=118, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76735, encryptionId=3207e6735ae, topicName=糖尿病治疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e6a1280, createdName=zhanglin3079, createdTime=Mon Jan 17 02:38:42 CST 2022, time=2022-01-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1270929, encodeId=ec5412e0929c6, content=<a href='/topic/show?id=4066981e99e' target=_blank style='color:#2F92EE;'>#降糖药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98179, encryptionId=4066981e99e, topicName=降糖药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Mon Aug 16 09:38:42 CST 2021, time=2021-08-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1404244, encodeId=feb0140424436, content=<a href='/topic/show?id=ff77e94785a' target=_blank style='color:#2F92EE;'>#网红#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79478, encryptionId=ff77e94785a, topicName=网红)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=981e2448917, createdName=caoliehu, createdTime=Mon Aug 16 09:38:42 CST 2021, time=2021-08-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1427544, encodeId=99fb142e544cb, content=<a href='/topic/show?id=221d685172' target=_blank style='color:#2F92EE;'>#EPA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6851, encryptionId=221d685172, topicName=EPA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4a9b4077760, createdName=gwc384, createdTime=Mon Aug 16 09:38:42 CST 2021, time=2021-08-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1034423, encodeId=b606103442359, content=顶刊就是不一样，质量很高，内容精彩！学到很多, beContent=null, objectType=article, channel=null, level=null, likeNumber=105, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=goodbing, createdTime=Sat Aug 14 21:38:42 CST 2021, time=2021-08-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1043734, encodeId=f3221043e3420, content=谢谢MedSci提供最新的资讯, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Sat Aug 14 21:38:42 CST 2021, time=2021-08-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1007906, encodeId=fad9100e906ab, content=学习学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=107, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=b3545492917, createdName=smart Ren, createdTime=Sat Aug 14 20:13:10 CST 2021, time=2021-08-14, status=1, ipAttribution=)]
    2022-01-17 zhanglin3079

    #糖尿病治疗#

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1214247, encodeId=91fa121424e06, content=<a href='/topic/show?id=16b6104504ef' target=_blank style='color:#2F92EE;'>#泰瑞帕肽#</a>大于<a href='/topic/show?id=1090e69928f' target=_blank style='color:#2F92EE;'>#索马鲁肽#</a>，更大于<a href='/topic/show?id=401e3230391' target=_blank style='color:#2F92EE;'>#利拉鲁肽#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=150, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=104504, encryptionId=16b6104504ef, topicName=泰瑞帕肽), TopicDto(id=76992, encryptionId=1090e69928f, topicName=索马鲁肽), TopicDto(id=32303, encryptionId=401e3230391, topicName=利拉鲁肽)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211210/ede9c51184aa4f54ae6c1164cfb8eeac/967dbf3eff2943c7bf3ccfec3a776ab0.JPG, createdBy=a33789389, createdName=病毒猎手, createdTime=Mon Apr 25 22:19:18 CST 2022, time=2022-04-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1062655, encodeId=1e9c1062655ef, content=新的方法，新的起点, beContent=null, objectType=article, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210826/7a6cce5e03844bcf8a6ee8a36dba8188/b15bf50504094d3aa56a8f1a32d3304c.jpg, createdBy=1d8c1533153, createdName=未来将来, createdTime=Thu Oct 21 17:31:07 CST 2021, time=2021-10-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1831273, encodeId=8b7518312e3c5, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Fri May 13 22:38:42 CST 2022, time=2022-05-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1990000, encodeId=b15f19900006b, content=<a href='/topic/show?id=3207e6735ae' target=_blank style='color:#2F92EE;'>#糖尿病治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=118, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76735, encryptionId=3207e6735ae, topicName=糖尿病治疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e6a1280, createdName=zhanglin3079, createdTime=Mon Jan 17 02:38:42 CST 2022, time=2022-01-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1270929, encodeId=ec5412e0929c6, content=<a href='/topic/show?id=4066981e99e' target=_blank style='color:#2F92EE;'>#降糖药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98179, encryptionId=4066981e99e, topicName=降糖药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Mon Aug 16 09:38:42 CST 2021, time=2021-08-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1404244, encodeId=feb0140424436, content=<a href='/topic/show?id=ff77e94785a' target=_blank style='color:#2F92EE;'>#网红#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79478, encryptionId=ff77e94785a, topicName=网红)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=981e2448917, createdName=caoliehu, createdTime=Mon Aug 16 09:38:42 CST 2021, time=2021-08-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1427544, encodeId=99fb142e544cb, content=<a href='/topic/show?id=221d685172' target=_blank style='color:#2F92EE;'>#EPA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6851, encryptionId=221d685172, topicName=EPA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4a9b4077760, createdName=gwc384, createdTime=Mon Aug 16 09:38:42 CST 2021, time=2021-08-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1034423, encodeId=b606103442359, content=顶刊就是不一样，质量很高，内容精彩！学到很多, beContent=null, objectType=article, channel=null, level=null, likeNumber=105, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=goodbing, createdTime=Sat Aug 14 21:38:42 CST 2021, time=2021-08-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1043734, encodeId=f3221043e3420, content=谢谢MedSci提供最新的资讯, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Sat Aug 14 21:38:42 CST 2021, time=2021-08-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1007906, encodeId=fad9100e906ab, content=学习学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=107, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=b3545492917, createdName=smart Ren, createdTime=Sat Aug 14 20:13:10 CST 2021, time=2021-08-14, status=1, ipAttribution=)]
    2021-08-16 minlingfeng

    #降糖药#

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=1214247, encodeId=91fa121424e06, content=<a href='/topic/show?id=16b6104504ef' target=_blank style='color:#2F92EE;'>#泰瑞帕肽#</a>大于<a href='/topic/show?id=1090e69928f' target=_blank style='color:#2F92EE;'>#索马鲁肽#</a>，更大于<a href='/topic/show?id=401e3230391' target=_blank style='color:#2F92EE;'>#利拉鲁肽#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=150, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=104504, encryptionId=16b6104504ef, topicName=泰瑞帕肽), TopicDto(id=76992, encryptionId=1090e69928f, topicName=索马鲁肽), TopicDto(id=32303, encryptionId=401e3230391, topicName=利拉鲁肽)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211210/ede9c51184aa4f54ae6c1164cfb8eeac/967dbf3eff2943c7bf3ccfec3a776ab0.JPG, createdBy=a33789389, createdName=病毒猎手, createdTime=Mon Apr 25 22:19:18 CST 2022, time=2022-04-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1062655, encodeId=1e9c1062655ef, content=新的方法，新的起点, beContent=null, objectType=article, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210826/7a6cce5e03844bcf8a6ee8a36dba8188/b15bf50504094d3aa56a8f1a32d3304c.jpg, createdBy=1d8c1533153, createdName=未来将来, createdTime=Thu Oct 21 17:31:07 CST 2021, time=2021-10-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1831273, encodeId=8b7518312e3c5, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Fri May 13 22:38:42 CST 2022, time=2022-05-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1990000, encodeId=b15f19900006b, content=<a href='/topic/show?id=3207e6735ae' target=_blank style='color:#2F92EE;'>#糖尿病治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=118, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76735, encryptionId=3207e6735ae, topicName=糖尿病治疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e6a1280, createdName=zhanglin3079, createdTime=Mon Jan 17 02:38:42 CST 2022, time=2022-01-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1270929, encodeId=ec5412e0929c6, content=<a href='/topic/show?id=4066981e99e' target=_blank style='color:#2F92EE;'>#降糖药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98179, encryptionId=4066981e99e, topicName=降糖药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Mon Aug 16 09:38:42 CST 2021, time=2021-08-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1404244, encodeId=feb0140424436, content=<a href='/topic/show?id=ff77e94785a' target=_blank style='color:#2F92EE;'>#网红#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79478, encryptionId=ff77e94785a, topicName=网红)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=981e2448917, createdName=caoliehu, createdTime=Mon Aug 16 09:38:42 CST 2021, time=2021-08-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1427544, encodeId=99fb142e544cb, content=<a href='/topic/show?id=221d685172' target=_blank style='color:#2F92EE;'>#EPA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6851, encryptionId=221d685172, topicName=EPA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4a9b4077760, createdName=gwc384, createdTime=Mon Aug 16 09:38:42 CST 2021, time=2021-08-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1034423, encodeId=b606103442359, content=顶刊就是不一样，质量很高，内容精彩！学到很多, beContent=null, objectType=article, channel=null, level=null, likeNumber=105, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=goodbing, createdTime=Sat Aug 14 21:38:42 CST 2021, time=2021-08-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1043734, encodeId=f3221043e3420, content=谢谢MedSci提供最新的资讯, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Sat Aug 14 21:38:42 CST 2021, time=2021-08-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1007906, encodeId=fad9100e906ab, content=学习学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=107, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=b3545492917, createdName=smart Ren, createdTime=Sat Aug 14 20:13:10 CST 2021, time=2021-08-14, status=1, ipAttribution=)]
    2021-08-16 caoliehu

    #网红#

    0

  7. [GetPortalCommentsPageByObjectIdResponse(id=1214247, encodeId=91fa121424e06, content=<a href='/topic/show?id=16b6104504ef' target=_blank style='color:#2F92EE;'>#泰瑞帕肽#</a>大于<a href='/topic/show?id=1090e69928f' target=_blank style='color:#2F92EE;'>#索马鲁肽#</a>，更大于<a href='/topic/show?id=401e3230391' target=_blank style='color:#2F92EE;'>#利拉鲁肽#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=150, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=104504, encryptionId=16b6104504ef, topicName=泰瑞帕肽), TopicDto(id=76992, encryptionId=1090e69928f, topicName=索马鲁肽), TopicDto(id=32303, encryptionId=401e3230391, topicName=利拉鲁肽)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211210/ede9c51184aa4f54ae6c1164cfb8eeac/967dbf3eff2943c7bf3ccfec3a776ab0.JPG, createdBy=a33789389, createdName=病毒猎手, createdTime=Mon Apr 25 22:19:18 CST 2022, time=2022-04-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1062655, encodeId=1e9c1062655ef, content=新的方法，新的起点, beContent=null, objectType=article, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210826/7a6cce5e03844bcf8a6ee8a36dba8188/b15bf50504094d3aa56a8f1a32d3304c.jpg, createdBy=1d8c1533153, createdName=未来将来, createdTime=Thu Oct 21 17:31:07 CST 2021, time=2021-10-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1831273, encodeId=8b7518312e3c5, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Fri May 13 22:38:42 CST 2022, time=2022-05-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1990000, encodeId=b15f19900006b, content=<a href='/topic/show?id=3207e6735ae' target=_blank style='color:#2F92EE;'>#糖尿病治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=118, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76735, encryptionId=3207e6735ae, topicName=糖尿病治疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e6a1280, createdName=zhanglin3079, createdTime=Mon Jan 17 02:38:42 CST 2022, time=2022-01-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1270929, encodeId=ec5412e0929c6, content=<a href='/topic/show?id=4066981e99e' target=_blank style='color:#2F92EE;'>#降糖药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98179, encryptionId=4066981e99e, topicName=降糖药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Mon Aug 16 09:38:42 CST 2021, time=2021-08-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1404244, encodeId=feb0140424436, content=<a href='/topic/show?id=ff77e94785a' target=_blank style='color:#2F92EE;'>#网红#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79478, encryptionId=ff77e94785a, topicName=网红)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=981e2448917, createdName=caoliehu, createdTime=Mon Aug 16 09:38:42 CST 2021, time=2021-08-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1427544, encodeId=99fb142e544cb, content=<a href='/topic/show?id=221d685172' target=_blank style='color:#2F92EE;'>#EPA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6851, encryptionId=221d685172, topicName=EPA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4a9b4077760, createdName=gwc384, createdTime=Mon Aug 16 09:38:42 CST 2021, time=2021-08-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1034423, encodeId=b606103442359, content=顶刊就是不一样，质量很高，内容精彩！学到很多, beContent=null, objectType=article, channel=null, level=null, likeNumber=105, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=goodbing, createdTime=Sat Aug 14 21:38:42 CST 2021, time=2021-08-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1043734, encodeId=f3221043e3420, content=谢谢MedSci提供最新的资讯, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Sat Aug 14 21:38:42 CST 2021, time=2021-08-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1007906, encodeId=fad9100e906ab, content=学习学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=107, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=b3545492917, createdName=smart Ren, createdTime=Sat Aug 14 20:13:10 CST 2021, time=2021-08-14, status=1, ipAttribution=)]
    2021-08-16 gwc384

    #EPA#

    0

  8. [GetPortalCommentsPageByObjectIdResponse(id=1214247, encodeId=91fa121424e06, content=<a href='/topic/show?id=16b6104504ef' target=_blank style='color:#2F92EE;'>#泰瑞帕肽#</a>大于<a href='/topic/show?id=1090e69928f' target=_blank style='color:#2F92EE;'>#索马鲁肽#</a>，更大于<a href='/topic/show?id=401e3230391' target=_blank style='color:#2F92EE;'>#利拉鲁肽#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=150, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=104504, encryptionId=16b6104504ef, topicName=泰瑞帕肽), TopicDto(id=76992, encryptionId=1090e69928f, topicName=索马鲁肽), TopicDto(id=32303, encryptionId=401e3230391, topicName=利拉鲁肽)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211210/ede9c51184aa4f54ae6c1164cfb8eeac/967dbf3eff2943c7bf3ccfec3a776ab0.JPG, createdBy=a33789389, createdName=病毒猎手, createdTime=Mon Apr 25 22:19:18 CST 2022, time=2022-04-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1062655, encodeId=1e9c1062655ef, content=新的方法，新的起点, beContent=null, objectType=article, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210826/7a6cce5e03844bcf8a6ee8a36dba8188/b15bf50504094d3aa56a8f1a32d3304c.jpg, createdBy=1d8c1533153, createdName=未来将来, createdTime=Thu Oct 21 17:31:07 CST 2021, time=2021-10-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1831273, encodeId=8b7518312e3c5, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Fri May 13 22:38:42 CST 2022, time=2022-05-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1990000, encodeId=b15f19900006b, content=<a href='/topic/show?id=3207e6735ae' target=_blank style='color:#2F92EE;'>#糖尿病治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=118, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76735, encryptionId=3207e6735ae, topicName=糖尿病治疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e6a1280, createdName=zhanglin3079, createdTime=Mon Jan 17 02:38:42 CST 2022, time=2022-01-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1270929, encodeId=ec5412e0929c6, content=<a href='/topic/show?id=4066981e99e' target=_blank style='color:#2F92EE;'>#降糖药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98179, encryptionId=4066981e99e, topicName=降糖药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Mon Aug 16 09:38:42 CST 2021, time=2021-08-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1404244, encodeId=feb0140424436, content=<a href='/topic/show?id=ff77e94785a' target=_blank style='color:#2F92EE;'>#网红#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79478, encryptionId=ff77e94785a, topicName=网红)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=981e2448917, createdName=caoliehu, createdTime=Mon Aug 16 09:38:42 CST 2021, time=2021-08-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1427544, encodeId=99fb142e544cb, content=<a href='/topic/show?id=221d685172' target=_blank style='color:#2F92EE;'>#EPA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6851, encryptionId=221d685172, topicName=EPA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4a9b4077760, createdName=gwc384, createdTime=Mon Aug 16 09:38:42 CST 2021, time=2021-08-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1034423, encodeId=b606103442359, content=顶刊就是不一样，质量很高，内容精彩！学到很多, beContent=null, objectType=article, channel=null, level=null, likeNumber=105, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=goodbing, createdTime=Sat Aug 14 21:38:42 CST 2021, time=2021-08-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1043734, encodeId=f3221043e3420, content=谢谢MedSci提供最新的资讯, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Sat Aug 14 21:38:42 CST 2021, time=2021-08-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1007906, encodeId=fad9100e906ab, content=学习学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=107, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=b3545492917, createdName=smart Ren, createdTime=Sat Aug 14 20:13:10 CST 2021, time=2021-08-14, status=1, ipAttribution=)]
    2021-08-14 goodbing

    顶刊就是不一样，质量很高，内容精彩！学到很多

    0

  9. [GetPortalCommentsPageByObjectIdResponse(id=1214247, encodeId=91fa121424e06, content=<a href='/topic/show?id=16b6104504ef' target=_blank style='color:#2F92EE;'>#泰瑞帕肽#</a>大于<a href='/topic/show?id=1090e69928f' target=_blank style='color:#2F92EE;'>#索马鲁肽#</a>，更大于<a href='/topic/show?id=401e3230391' target=_blank style='color:#2F92EE;'>#利拉鲁肽#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=150, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=104504, encryptionId=16b6104504ef, topicName=泰瑞帕肽), TopicDto(id=76992, encryptionId=1090e69928f, topicName=索马鲁肽), TopicDto(id=32303, encryptionId=401e3230391, topicName=利拉鲁肽)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211210/ede9c51184aa4f54ae6c1164cfb8eeac/967dbf3eff2943c7bf3ccfec3a776ab0.JPG, createdBy=a33789389, createdName=病毒猎手, createdTime=Mon Apr 25 22:19:18 CST 2022, time=2022-04-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1062655, encodeId=1e9c1062655ef, content=新的方法，新的起点, beContent=null, objectType=article, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210826/7a6cce5e03844bcf8a6ee8a36dba8188/b15bf50504094d3aa56a8f1a32d3304c.jpg, createdBy=1d8c1533153, createdName=未来将来, createdTime=Thu Oct 21 17:31:07 CST 2021, time=2021-10-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1831273, encodeId=8b7518312e3c5, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Fri May 13 22:38:42 CST 2022, time=2022-05-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1990000, encodeId=b15f19900006b, content=<a href='/topic/show?id=3207e6735ae' target=_blank style='color:#2F92EE;'>#糖尿病治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=118, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76735, encryptionId=3207e6735ae, topicName=糖尿病治疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e6a1280, createdName=zhanglin3079, createdTime=Mon Jan 17 02:38:42 CST 2022, time=2022-01-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1270929, encodeId=ec5412e0929c6, content=<a href='/topic/show?id=4066981e99e' target=_blank style='color:#2F92EE;'>#降糖药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98179, encryptionId=4066981e99e, topicName=降糖药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Mon Aug 16 09:38:42 CST 2021, time=2021-08-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1404244, encodeId=feb0140424436, content=<a href='/topic/show?id=ff77e94785a' target=_blank style='color:#2F92EE;'>#网红#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79478, encryptionId=ff77e94785a, topicName=网红)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=981e2448917, createdName=caoliehu, createdTime=Mon Aug 16 09:38:42 CST 2021, time=2021-08-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1427544, encodeId=99fb142e544cb, content=<a href='/topic/show?id=221d685172' target=_blank style='color:#2F92EE;'>#EPA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6851, encryptionId=221d685172, topicName=EPA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4a9b4077760, createdName=gwc384, createdTime=Mon Aug 16 09:38:42 CST 2021, time=2021-08-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1034423, encodeId=b606103442359, content=顶刊就是不一样，质量很高，内容精彩！学到很多, beContent=null, objectType=article, channel=null, level=null, likeNumber=105, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=goodbing, createdTime=Sat Aug 14 21:38:42 CST 2021, time=2021-08-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1043734, encodeId=f3221043e3420, content=谢谢MedSci提供最新的资讯, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Sat Aug 14 21:38:42 CST 2021, time=2021-08-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1007906, encodeId=fad9100e906ab, content=学习学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=107, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=b3545492917, createdName=smart Ren, createdTime=Sat Aug 14 20:13:10 CST 2021, time=2021-08-14, status=1, ipAttribution=)]
    2021-08-14 misszhang

    谢谢MedSci提供最新的资讯

    0

  10. [GetPortalCommentsPageByObjectIdResponse(id=1214247, encodeId=91fa121424e06, content=<a href='/topic/show?id=16b6104504ef' target=_blank style='color:#2F92EE;'>#泰瑞帕肽#</a>大于<a href='/topic/show?id=1090e69928f' target=_blank style='color:#2F92EE;'>#索马鲁肽#</a>，更大于<a href='/topic/show?id=401e3230391' target=_blank style='color:#2F92EE;'>#利拉鲁肽#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=150, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=104504, encryptionId=16b6104504ef, topicName=泰瑞帕肽), TopicDto(id=76992, encryptionId=1090e69928f, topicName=索马鲁肽), TopicDto(id=32303, encryptionId=401e3230391, topicName=利拉鲁肽)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211210/ede9c51184aa4f54ae6c1164cfb8eeac/967dbf3eff2943c7bf3ccfec3a776ab0.JPG, createdBy=a33789389, createdName=病毒猎手, createdTime=Mon Apr 25 22:19:18 CST 2022, time=2022-04-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1062655, encodeId=1e9c1062655ef, content=新的方法，新的起点, beContent=null, objectType=article, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210826/7a6cce5e03844bcf8a6ee8a36dba8188/b15bf50504094d3aa56a8f1a32d3304c.jpg, createdBy=1d8c1533153, createdName=未来将来, createdTime=Thu Oct 21 17:31:07 CST 2021, time=2021-10-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1831273, encodeId=8b7518312e3c5, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Fri May 13 22:38:42 CST 2022, time=2022-05-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1990000, encodeId=b15f19900006b, content=<a href='/topic/show?id=3207e6735ae' target=_blank style='color:#2F92EE;'>#糖尿病治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=118, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76735, encryptionId=3207e6735ae, topicName=糖尿病治疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e6a1280, createdName=zhanglin3079, createdTime=Mon Jan 17 02:38:42 CST 2022, time=2022-01-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1270929, encodeId=ec5412e0929c6, content=<a href='/topic/show?id=4066981e99e' target=_blank style='color:#2F92EE;'>#降糖药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98179, encryptionId=4066981e99e, topicName=降糖药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Mon Aug 16 09:38:42 CST 2021, time=2021-08-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1404244, encodeId=feb0140424436, content=<a href='/topic/show?id=ff77e94785a' target=_blank style='color:#2F92EE;'>#网红#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79478, encryptionId=ff77e94785a, topicName=网红)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=981e2448917, createdName=caoliehu, createdTime=Mon Aug 16 09:38:42 CST 2021, time=2021-08-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1427544, encodeId=99fb142e544cb, content=<a href='/topic/show?id=221d685172' target=_blank style='color:#2F92EE;'>#EPA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6851, encryptionId=221d685172, topicName=EPA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4a9b4077760, createdName=gwc384, createdTime=Mon Aug 16 09:38:42 CST 2021, time=2021-08-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1034423, encodeId=b606103442359, content=顶刊就是不一样，质量很高，内容精彩！学到很多, beContent=null, objectType=article, channel=null, level=null, likeNumber=105, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=goodbing, createdTime=Sat Aug 14 21:38:42 CST 2021, time=2021-08-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1043734, encodeId=f3221043e3420, content=谢谢MedSci提供最新的资讯, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Sat Aug 14 21:38:42 CST 2021, time=2021-08-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1007906, encodeId=fad9100e906ab, content=学习学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=107, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=b3545492917, createdName=smart Ren, createdTime=Sat Aug 14 20:13:10 CST 2021, time=2021-08-14, status=1, ipAttribution=)]
    2021-08-14 smart Ren

    学习学习

    0

以上为热门评论，梅斯医学App还有更多内容

相关资讯

Eur J Heart Fail：达格列净对射血分数降低的心衰患者贫血的影响

达格列净是否有助于改善心力衰竭患者的贫血症状？

JASN：达格列净对4期慢性肾脏病的影响

在4期CKD和蛋白尿患者中，达格列净的益处与DAPA-CKD试验中观察到的总体益处一致，没有证据表明其风险增加。

Circulation：达格列净治疗对HFrEF患者肾功能和预后的效益

很多射血分数降低的心衰患者（HFrEF）都存在慢性肾病，使药物管理复杂化、预后不良。本文评估了达格列净对HFrEF患者（根据基础肾功能）的安全性和疗效，同时评估达格列净对肾功能的影响。

Circulation：达格列净可明显改善慢性肾病患者的多种不良预后结局！

本研究评估这些患者发生心血管和肾脏事件的相对风险，以及达格列净对这两种事件的影响，并根据有无心血管疾病进行分层。

Journal of the American Society of Nephrology：达格列净对晚期肾病患者有效且安全

之前发表在circulation上的一项研究表明达格列净可降低慢性心肾病患者（无论有无合并2型糖尿病）的肾衰、心血管性死亡或心衰住院的风险，延长其存活期，且不受有无合并心血管疾病的影响。那达格列净对4

Lancet Diabetes Endocrinol：达格列净可否改善有心脏代谢风险因素的新冠肺炎患者的临床预后？

SGLT2抑制剂达格列净对心脏和肾脏具有显著的保护作用，是否能改善有心脏代谢风险因素的新冠肺炎患者的临床预后？

拓展阅读

Eur Heart J-Card Pha：钠-葡萄糖共转运蛋白2抑制剂在癌症和糖尿病患者中的疗效分析

在积极治疗的2型糖尿病癌症患者中，钠-葡萄糖共转运蛋白2抑制剂的使用可能与全因死亡率和HF住院风险的显著降低有关。

糖尿病遗传「重女轻男」？北大研究发现：妈妈有糖尿病，孩子患病风险高 2.55 倍！

该研究对中国北方家庭展开了深入探索，试图揭开父母糖尿病遗传给后代的神秘面纱。

Cardiovasc Res/Cardiovasc Diabetol 江苏大学附属医院王中群团队解码糖尿病血管钙化病变新机制

王中群团队研究发现，DJ-1 调控糖尿病血管微钙化，还构建空间多组学图谱揭示血管钙化、平滑肌细胞转化及代谢重编程，为防治提供新方向。

Eur Heart J：新型整数风险评分预测慢性肾病合并 2 型糖尿病患者高钾血症风险

慢性肾脏疾病和2型糖尿病患者新发高钾血症的整数风险评分可以促进量身定制的治疗策略，减轻高风险患者的高钾血症。

再添新证！多吃猪牛羊肉，结直肠癌风险升高17％？最新研究：多吃红肉不仅易痴呆，还会促癌，同时增加糖尿病风险！但这些食物可有效替代

炫肉也要“点到为止”~

中国首个！异体通用型再生胰岛移植治疗1型糖尿病疗法获批IND，糖尿病治愈曙光初现

国内两款异体胰岛细胞疗法获批临床，技术路线各具特色​